• Explore /
  • Poster
  • / A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.

A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma.

Abstract Poster

Authors

null

Jason A. Konner

Memorial Sloan Kettering Cancer Center, New York, NY

Jason A. Konner , Nicole N Boucicaut , Roisin Eilish O'Cearbhaill , Dmitriy Zamarin , Vicky Makker , Paul Sabbatini , William P. Tew , Karen Anne Cadoo , Rachel N. Grisham , Carol Aghajanian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02121990

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5572)

DOI

10.1200/JCO.2017.35.15_suppl.5572

Abstract #

5572

Poster Bd #

394

Abstract Disclosures

Similar Posters

First Author: Deborah Kay Armstrong

First Author: Andreas Rimner

First Author: Sina Vatandoust

First Author: D. S. Dizon